ERES East Resources Acquisition Company

Emerging Biotechnology Organization Awards $1.3 Million Study Extension to eResearchTechnology for Cardiac Safety Monitoring and Information Distribution Services Overall Agreement Now Totals More than $4.2 Million, and Includes Thorough ECG Study Profile PHILADELPHIA, May 6 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), , a leading provider of centralized electrocardiographic (ECG) collection and interpretation services, announced today that it has received an agreement for about $1.3 million in additional cardiac safety monitoring and services from an emerging biotechnology organization for one of its drug candidates in clinical development. The additional award brings to more than $4.2 million the total services contracted to eRT for this single clinical trial. The agreement covers an extension to a significant Phase III study for which eRT was already providing comprehensive support, including the provision, training and ongoing assistance required for effective use of digital 12-lead Holter equipment designed to facilitate 24-hour digital recording of cardiac safety data that is subsequently provided to eRT for analysis. The extension will enable collection and analysis of additional cardiac safety data that will be critical in determining the definitive cardiac effects of this new drug candidate. eRT will perform digital collection, measurement, interpretation, review, and distribution of cardiac safety data through its EXPeRT workflow enabled data handling technology, the first solution in production that was designed explicitly to meet emerging international regulatory guidance and technical standards. The study extension is targeted for completion over a 90-day period. "eRT's continuous 12-lead ECG recording platform has proven invaluable to this sponsor's desire to further enhance the cardiac safety data being collected and analyzed for this important compound," said Scott Grisanti, senior vice president of business development and chief marketing officer at eRT. "This extension further demonstrates the importance of safety profiling in later stage development and illustrates that eRT's scalable capacity is key to the ability to rapidly deliver on unplanned increases in study demands." Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development. Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. The sponsor may cancel this agreement at its sole discretion. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company's financial results can be found in the company's Reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission. DATASOURCE: eResearchTechnology, Inc. CONTACT: Joan Sterlacci, eResearchTechnology, Inc., +1-908-203-6473; or Matt Hayden, Hayden Communications, +1-858-456-4533, for eResearchTechnology, Inc. Web site: http://www.ert.com/

Copyright